As cellular O-GlcNAcylation, which can be endored by either OGA inhibition or OGT activation, can enhance BTZ sensitivity in de novo BTZ-resistant cells via tBid [31], it is interesting to know that expression of OGT, BCL2L1, and BAX cooperatively predicts the clinical outcome in MCL patients. This evidence concerns the gene OGA and mantle cell lymphoma.